Facebook
Twitter
LinkedIn
ForwardEarly Career Investigators Workshop (2018)
The collaborative Early-Career Investigators Workshop (ECIW) provides an opportunity for promising junior surgeon-scientists to receive individualized mentoring, insights into the scientific review process, information about independent funding sources, and grant writing guidance. The goal of the workshop is to motivate and support surgeon-scientists in the early stages of their careers by providing an outstanding program led by established, well-funded investigators (both surgeon-scientists and other investigators) in urologic research.
This 2.5-day workshop and its activities are geared for individuals planning to submit competitive research proposals to the major funders of urologic research. The workshop agenda fosters research career success by providing participants with a solid foundation for successful grant writing. The workshop and activities include interaction with senior scientific advisors in small group and individual sessions. The program consists of four major components: 1) Didactic Instruction 2)Individual Proposal Review and Critique 3)Grant Review/ Revision and 4) Mock Study Section.
Target Audience
- Researcher
- Urologist
- Resident
Learning Objectives
After completing this activity, participants will be able to:
- Describe the cutting-edge and developing areas in basic and translational research, and identify components of their research efforts that intersect with or expand upon these;
- Develop and refine a compelling, innovative, and testable hypothesis;
- Develop a reasonable and ‘do-able’ experimental plan that adequately tests the stated hypothesis;
- Identify potential limitations of the proposed experimental plan and alternative experimental outcomes, and develop responsive alternative experimental approaches;
- Expand the initial concepts presented in the application to optimally project future directions, concepts, and studies;
- Avoid common pitfalls that typically dampen the enthusiasm of grant reviewers; and
- Describe the necessary administrative (nuts-and-bolts) components of NIH grant applications.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Day Two: Friday, October 12, 2018
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
7:30 AM | Attendee Arrival (continental breakfast available) |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
8:00 AM | Welcome, Faculty and Participant Introductions, | Carolyn Best, PhD American Urological Association
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
8:45 AM | Setting the Stage: An Overview of the State of Urology Research and Funding
| Carolyn Best, PhD American Urological Association
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
9:00 AM | Tech/Software for Grant Writing | Michael Hsieh, MD, PhD Biomedical Research Institute,
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
9:20 AM | Common Grantsmanship Pitfalls | Dolores J. Lamb, PhD, HCLD (ABB) Weill Cornell Medical College |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
9:40 AM | Specific Aims Workshop | Erika Wolff, PhD University of Washington
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
10:20 AM | Break |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
10:30 AM | Mock Peer Review Study Section | Faculty Panel
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
12:30 PM | Lunch (assigned seating by research interest with faculty) | See sticker on back of nametag
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1:20 PM | Transition to Breakout Groups |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1:30 PM | Concurrent Training Tracks – Session One: |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Advanced Grant Development Group: Individual Meetings with Faculty Mentors:
| 3rd Floor Executive Boardroom |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Time | Mentor | Advanced Group Mentee |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1:30 | Dr. Peter Clark | Dr. Abbosh |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1:30 | Dr. Dolores Lamb | Dr. Li |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1:30 | Dr. John Wei | Dr. Garg |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1:30 | Dr. Patricia Morris | Dr. Gabrielsen |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2:30 |
Dr. Peter Clark |
Dr. Krane |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2:30 | Dr. Rosalyn Adam | Dr. Sundi |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2:30 | Dr. Aria Olumi | Dr. Kim |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2:30 | Dr. Michael Hsieh | Dr. Van Batavia |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2:30 | Dr. Firouz Daneshgari | Dr. Lee |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3:30 |
Dr. Rosalyn Adam |
Dr. Pietzak |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3:30 | Dr. Aria Olumi | Dr. Nair |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3:30 | Dr. Michael Hsieh | Dr. Sysoeva |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3:30 | Dr. Firouz Daneshgari | Dr. Mossanen |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3:30 | Dr. Todd Purves | Dr. Chu
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1:30 PM | Early Grant Development Group (and optional for Advanced Development Group):
| Auditorium |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1:30PM | Selling Yourself Through Your NIH Biosketch | J. Todd Purves, MD, PhD Duke University
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1:50 PM | How to Start a Lab as a Junior Faculty | Douglas Strand, PhD University of Texas Southwestern
Michael Hsieh, MD, PhD Biomedical Research Institute,
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2:10 PM | Establishing Effective Career Development Goals and Translation | Douglas Strand, PhD University of Texas Southwestern
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2:30 PM | Break
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2:45 PM | Personality Poker – A Professional Development Exercise
| John Wei, MD, MS University of Michigan |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
4:15 PM | Break and Transition Time
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
4:30 PM | Concurrent Training Tracks – Session Two: |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Advanced Grant Development Group: Independent Work Time (proposal writing and editing)
| 3rd Floor Executive Boardroom and First Floor Conference Room (writing) |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Early Grant Development Group: Small Group Meetings with Faculty Mentors:
| Auditorium |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Table | Mentor | Early Group Mentees |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Table 1 | Dr. Dolores Lamb, Dr. Patricia Morris | Drs. Kovac, Rotinen, and Gano |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Table 2 | Dr. John Wei and Dr. Erika Wolff | Drs. Harris, Hampson, and Gill |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Table 3 | Dr. Aria Olumi and Dr. Douglas Strand
| Drs. Guerrios-Rivera and Galván-Alvarado |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Table 4 | Dr. Rosalyn Adam | Drs. Sfakianos, Scotland, and Haifler |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Table 5 | Dr. Michael Hsieh | Dr. Kelly |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Table 6 | Dr. Firouz Daneshgari | Drs. Amin, Campbell, and Gonzalez |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Table 7 | Dr. Margot Damaser and Dr. Todd Purves | Dr. Dhar |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Table 8 | Dr. Peter Clark
| Drs. Mark and Sanchez |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
5:30 PM | Independent Work Time (Early and Advanced Groups) (Specific Aims writing and editing)
| Auditorium |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
6:00 PM | Networking Dinner
| Auditorium
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
7:00 PM | Adjourn for the day |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Day Three: Saturday, October 13, 2018
| |||||||||||||
7:30 AM | Attendee Arrival (continental breakfast available) |
| |||||||||||
7:30 AM | Faculty Meeting – Briefing to prep for the day – All Faculty
| 1st Floor Conference Room | |||||||||||
8:00 AM | Welcome and Goals for the Day | Carolyn Best, PhD American Urological Association
| |||||||||||
8:15 AM | The Importance of Translating Research into Clinical Impact | Margot Damaser, PhD Cleveland Clinic
| |||||||||||
8:35 AM | Project Management Techniques for Research | Erika Wolff, PhD University of Washington
| |||||||||||
8:55 AM | Negotiating the Unique Challenges of MD vs PhD Research Careers | Rosalyn Adam, PhD Boston Children’s Hospital
Peter Clark, MD Carolinas HealthCare System
| |||||||||||
9:40 AM | Transitioning from a K to an R | Aria Olumi, MD Beth Israel Deaconess Medical Center and Harvard Medical School
| |||||||||||
10:00 AM | Break
|
| |||||||||||
10:15 AM | Advanced Grant Development Group: Presentations
|
| |||||||||||
10:20 | Defining the role of the chloride transport channel, CLCN4, in Sertoli cell iron transport and spermatogenesis | Joseph Scott Gabrielsen, MD, PhD Baylor College of Medicine | |||||||||||
10:25 | Reliability of estimated glomerular filtration rates in patients with spina bifida. | David I. Chu, MD, MSCE Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University
| |||||||||||
10:30 | Assessment of treatment burden in older adults with superficial bladder cancer and multiple chronic conditions | Tullika Garg, MD, MPH Geisinger Health System | |||||||||||
10:35 | Exosomes as biomarkers of aggressive disease in clear cell renal cell carcinoma | Louis Spencer Krane, MD Tulane University School of Medicine | |||||||||||
10:40 | The relationship between prostate magnetic resonance imaging and inflammation | Eric Hwan Kim, MD Washington University School of Medicine
| |||||||||||
10:45 | Healthy father, healthy sperm? How the sperm epigenome is altered by environmental perturbations | Xin Li, PhD University of Rochester Medical Center | |||||||||||
10:50 | Molecular determinants of response and resistance to intravesical BCG immunotherapy in “superficial” bladder cancer | Eugene Jon Pietzak, MD Memorial Sloan Kettering Cancer Center | |||||||||||
10:55 | Modulation of natural killer and myeloid derived suppressor cells to enhance bladder cancer immunotherapy | Debasish Sundi, MD Ohio State University Comprehensive Cancer Center
| |||||||||||
11:00 | Strategies to identify and optimize predictive biomarkers of disease recurrence following immunotherapy of prostate | Sujit S. Nair, PhD Icahn School of Medicine at Mount Sinai | |||||||||||
11:05 | Multicomponent approach to prehabilitation for radical cystectomy patients | Matthew Mossanen, MD, MPH Brigham and Women's Hospital
| |||||||||||
11:10 | Deciphering the role of corticotropin-releasing hormone expressing neurons in Barrington's nucleus on volitional voiding: Can social stress alterations in voiding phenotype be reversed by manipulating BN? | Jason Van Batavia, MD Children’s Hospital of Philadelphia | |||||||||||
11:15 | Contribution of antibiotic resistant uropathogens to spreading of drug resistance genes | Tatyana A. Sysoeva, PhD University of Alabama, Huntsville
| |||||||||||
11:20 | Driver mutations, immune microenvironment, and response to immune checkpoint blockade in clear cell renal cell carcinoma | Philip Abbosh, MD, PhD Fox Chase Cancer Center | |||||||||||
11:25 | Developing predictive models for stress urinary incontinence surgery outcomes | Una Lee, MD Virginia Mason Medical Center
| |||||||||||
11:30 AM | Faculty Feedback
|
| |||||||||||
12:00 PM | Lunch
|
| |||||||||||
12:45 PM | Workshop/Writing Time
| All faculty available | |||||||||||
1:45 PM | Lessons Learned, Feedback from Mentors, Q&A
|
| |||||||||||
2:15 PM | Meeting Wrap up and Adjourn Workshop
| Shuttles will be available to take participants to BWI Airport and Amtrak Train Station.
| |||||||||||
2:30 PM | Faculty/Steering Committee Meeting: Overview of ECIW
| First Floor Conference Room | |||||||||||
3:30 PM | Adjourn | Shuttles will be available to take faculty to BWI Airport and Amtrak Train Station. | |||||||||||
Faculty and Speaker Disclosures: | |||
| |||
Name | Company | Role | Financial |
Michael Abern, MD | Department of Defense Prostate Cancer Research Program | Scientific Study or Trial | Yes |
American Urological Association Office of Education | Consultant or Advisor | Yes | |
Department of Defense Prostate Cancer Research Program | Consultant or Advisor | Yes | |
Rosalyn Adam, PhD | Society for Basic Urologic Research (SBUR) | Leadership Position | No |
Peter Clark, MD | Galil Medical | Consultant or Advisor | No |
Genentech | Consultant or Advisor | No | |
Margot Damaser, PhD | Novartis | Scientific Study or Trial | Yes |
Medtronic | Scientific Study or Trial | No | |
Society for Pelvic Research (SPR) | Leadership Position | No | |
California Institute of Regenerative Medicine | Consultant or Advisor | Yes | |
Theratome Bio LLC | Scientific Study or Trial | No | |
Ellie Daniels, MD, MPH | American Cancer Society | Employee | Yes |
Dolores Lamb, PhD | National Institutes of Health (NIH) | Scientific Study or Trial; Other | No |
American Society for Reproductive Medicine | Leadership Position | No | |
The Society of Women in Urology (SWIU) | Leadership Position | Yes | |
National Institute of Child Health and Human Development (NICHD) | Scientific Study or Trial | No | |
Cellmatrix | Consultant or Advisor | Yes | |
American Board of Bioanalysts | Leadership Position | Yes | |
American Association of Bioanalysts | Leadership Position | Yes | |
Women in Endocrinology | Leadership Position | Yes | |
Victor Nitti, MD | Astellas | Health Publishing, Scientific Study or Trial | No |
Allergan | Health Publishing, Scientific Study or Trial | No | |
Serentiy Pharmaceuticals | Investment Interest | Yes | |
Medtronic | Scientific Study or Trial | No | |
Aria Olumi, MD | More Health | Consultant or Advisor | Yes |
John Wei, MD | Histosonics | Scientific Study or Trial | No |
National Cancer Institute (NCI) | Scientific Study or Trial | No | |
| |||
The following faculty members have no disclosures to report: Tamara Bavendam, MD; Carolyn Best, PhD; Krystal Brinson, PhD; Firouz Daneshgari, MD; Michael Hsieh, MD, PhD; Candace Kerr, PhD; Donna Kimbark, PhD; Patricia Morris, PhD; J. Todd Purves, MD; Sergei Radaev, PhD; Tracy Rankin, PhD; Douglas Strand, PhD; Erika Wolff, PhD
The following speakers have no disclosures to report: Philip Abbosh, MD, PhD; David Chu, MD; Joseph Scott Gabrielsen, MD, PhD; Tulika Garg, MD, MPH; Eric H. Kim, MD; Louis S. Krane, MD; Una Lee, MD; Xin Li, PhD; Matthew Mossanen, MD; Sujit Nair, PhD; Eugene Pietzak III, MD;
| |||
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this live activity for a maximum of ___ AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 CreditTM.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Conflict of Interest Review Work Group or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
AUA PARTICIPANT INFORMATION & POLICIES
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Consent to Use of Photographic Images: Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the attendee's image or voice in photographs and electronic reproductions of such meetings and activities.
Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.
Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
Special Assistance/Dietary Needs: The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.
Available Credit
- 17.75 AMA PRA Category 1 Credit™
- 17.75 Non-Physician Participation